The compelling preclinical data in TNBC, particularly in ADC-resistant models, suggests azenosertib could address a growing unmet need as ADCs move into first-line TNBC treatment. This pipeline expansion potential, combined with strong validation of the ovarian cancer target population, could drive positive re-rating. Monitor for clinical trial initiation in TNBC and upcoming data from ongoing ovarian cancer studies.
Price Chart
Executive Summary
Zentalis Pharmaceuticals presented preclinical data at AACR 2026 showing that its investigational WEE1 inhibitor azenosertib demonstrates strong antitumor activity in triple-negative breast cancer (TNBC), including complete responses in ADC-resistant models. The company also presented real-world evidence confirming poor outcomes for Cyclin E1-positive ovarian cancer patients, reinforcing the unmet need for azenosertib in this population.
Key Facts
- Azenosertib combinations induced complete tumor responses in 7 of 8 mice (87.5%) in a TNBC model resistant to sacituzumab govitecan
- Prevented tumor progression in 8 of 8 mice for over 52 days vs. 100% progression within 30 days with enfortumab vedotin alone
- Azenosertib monotherapy showed 42-99% tumor growth inhibition across 12 TNBC models
- Cyclin E1-positive ovarian cancer patients had significantly worse outcomes: 13.2-14.9 months time to next treatment vs. 19.5 months for Cyclin E1-negative patients (p<0.002)
- Azenosertib has Fast Track Designation from FDA for Cyclin E1-positive platinum-resistant ovarian cancer
Financial Impact
Potential pipeline expansion into TNBC market, which could significantly increase peak sales potential beyond current ovarian cancer focus
Risk Factors
- Preclinical data may not translate to human clinical efficacy
- Competitive landscape in TNBC is rapidly evolving with multiple ADCs and targeted therapies in development
- Company has limited financial resources and may need to raise capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001725160-26-000020 |
| Exhibit: ex991aacr2026datapressrele.htm | 0001725160-26-000020 |
| Exhibit: ex993-jeongetal_realworl.htm | 0001725160-26-000020 |
| Exhibit: ex992-leeetalazenointnbc.htm | 0001725160-26-000020 |
| Document: 0001725160-26-000020-index-headers.html | 0001725160-26-000020 |
| Document: 0001725160-26-000020-index.html | 0001725160-26-000020 |
| Document: 0001725160-26-000020.txt | 0001725160-26-000020 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 8-K | $3.71 $3.13 | ▲ +15.52% | ▲ +13.54% | $2.54 (+31.58%) |
Aug 14, 2026 7w ago | Press Release | $3.56 $3.50 | ▲ +1.69% | ▼ −0.31% | $2.54 (+28.79%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.75 $4.88 | ▲ +30.13% | ▲ +28.35% | $2.54 (−32.40%) |
Jun 1, 2026 17w ago | Press Release | $3.95 $4.36 | ▲ +10.25% | ▲ +11.82% | $2.54 (−35.82%) |
May 21, 2026 19w ago | Press Release | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.54 (−37.56%) |
May 21, 2026 19w ago | 8-K | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.54 (−37.56%) |
May 12, 2026 20w ago | 8-K | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.54 (−40.77%) |
May 12, 2026 20w ago | Press Release | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.54 (−40.77%) |
Apr 21, 2026 23w ago | Press Release | $3.99 $3.63 | ▼ −9.02% | ▼ −13.94% | $2.54 (−36.47%) |
Apr 17, 2026 23w ago | Press Release | $4.64 $4.09 | ▼ −11.85% | ▼ −17.22% | $2.54 (−45.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access